As we demonstrated the feasibility of monitoring PD-L1 (+) CTCs in this study, this CTC subgroup could potentially act as a biomarker to monitor the immune activation in tumor to facilitate treatment selection for combination with immunotherapies. The gene discussed is CD274; the disease is neoplasm.